{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:59:02Z","timestamp":1787702342540,"version":"build-2784847793"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["836031015"],"award-info":[{"award-number":["836031015"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objectives<\/jats:title>\n<jats:p>To assess the cost-effectiveness of various combinations of urate lowering therapy (ULT) and anti-inflammatory treatment in the management of newly diagnosed gout patients, from the Dutch societal perspective.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A probabilistic patient-level simulation estimating costs and quality-adjusted life years (QALYs) comparing gout and hyperuricemia treatment strategies was performed. ULT options febuxostat, allopurinol and no ULT were considered. Flare treatments naproxen, colchicine, prednisone, and anakinra were considered. A Markov Model was constructed to simulate gout disease. Health states were no flare, and severe pain, mild pain, moderate pain, or no pain in the presence of a flare. Model input was derived from patient level clinical trial data, meta-analyses or from previously published health-economic evaluations. The results of probabilistic sensitivity analyses were presented using incremental cost-effectiveness ratios (ICERs), and summarized using cost-effectiveness acceptability curves (CEACs). Scenario analyses were performed.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>The ICER for allopurinol versus no ULT was \u20ac1,381, when combined with naproxen. Febuxostat yielded the highest utility, but also the highest costs (\u20ac4,385 vs. \u20ac4,063 for allopurinol), resulting in an ICER of \u20ac25,173 when compared to allopurinol. No ULT was not cost-effective, yielding the lowest utility. For the gout flare medications, comparable effects on utility were achieved. Combined with febuxostat, naproxen was the cheapest option (\u20ac4,404), and anakinra the most expensive (\u20ac4,651). The ICER of anakinra compared to naproxen was \u20ac818,504. Colchicine and prednisone were dominated by naproxen.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Allopurinol and febuxostat were both cost-effective compared to No ULT. Febuxostat was cost-effective in comparison with allopurinol at higher willingness-to-pay thresholds. For treating gout flares, colchicine, naproxen and prednisone offered comparable health economic implications, although naproxen was the favoured option.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0261940","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T18:31:26Z","timestamp":1643394686000},"page":"e0261940","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9859-1034","authenticated-orcid":true,"given":"Celine Johanna","family":"van de Laar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn A. H.","family":"Oude Voshaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiwenn J.","family":"AL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart A. F. J.","family":"van de Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"issue":"8","key":"pone.0261940.ref001","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1136\/annrheumdis-2013-204647","article-title":"The global burden of gout: estimates from the Global Burden of Disease 2010 study","volume":"73","author":"E Smith","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"pone.0261940.ref002","article-title":"Quality of life and disability in patients with treatment-failure gout","author":"MA Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"pone.0261940.ref003","article-title":"Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy","author":"NL Edwards","year":"2011","journal-title":"J Med Econ"},{"issue":"3","key":"pone.0261940.ref004","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/acr.23607","article-title":"Gout, Hyperuricemia, and Crystal\u2010Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout","volume":"71","author":"D Bursill","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"pone.0261940.ref005","article-title":"2012 American college of rheumatology guidelines for management of gout. part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","author":"D Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"pone.0261940.ref006","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","author":"P Richette","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"key":"pone.0261940.ref007","doi-asserted-by":"crossref","DOI":"10.1080\/14656566.2017.1351945","volume-title":"Current and future therapies for gout","author":"T Pascart","year":"2017"},{"key":"pone.0261940.ref008","article-title":"Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial","author":"CA Janssen","year":"2019","journal-title":"Rheumatology"},{"key":"pone.0261940.ref009","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States","author":"CG Helmick","year":"2008","journal-title":"Part I. Arthritis Rheum"},{"key":"pone.0261940.ref010","article-title":"Cost-Effectiveness Analysis of Allopurinol Versus Febuxostat in Chronic Gout Patients: A U.S. Payer Perspective","author":"PK Gandhi","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"pone.0261940.ref011","article-title":"Febuxostat in the management of gout: a cost-effectiveness analysis","author":"LJ Smolen","year":"2015","journal-title":"J Med Econ"},{"issue":"9","key":"pone.0261940.ref012","doi-asserted-by":"crossref","first-page":"617","DOI":"10.7326\/M14-0227","article-title":"Cost-effectiveness of allopurinol and febuxostat for the management of gout","volume":"161","author":"E Jutkowitz","year":"2014","journal-title":"Ann Intern Med"},{"key":"pone.0261940.ref013","article-title":"Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial","author":"HJ Janssens","year":"2008","journal-title":"Lancet"},{"key":"pone.0261940.ref014","article-title":"Kostenhandleiding","author":"L Hakkaart-van Roijen","year":"2015","journal-title":"Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg"},{"key":"pone.0261940.ref015","unstructured":"Saase L, Zwaap J, Knies S, Meijden van der C, Staal P, Heiden van der L. Cost-effectiveness in daily practice. 2015;64. Available from: https:\/\/www.zorginstituutnederland.nl\/binaries\/content\/documents\/zinl-www\/documenten\/publicaties\/rapporten-en-standpunten\/2015\/1506-kosteneffectiviteit-in-de-praktijk\/Kosteneffectiviteit+in+de+praktijk.pdf"},{"key":"pone.0261940.ref016","article-title":"Serum urate levels and gout flares: Analysis from managed care data","author":"CA Sarawate","year":"2006","journal-title":"J Clin Rheumatol"},{"issue":"7387","key":"pone.0261940.ref017","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","article-title":"Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses","volume":"326","author":"F Song","year":"2003","journal-title":"BMJ"},{"key":"pone.0261940.ref018","article-title":"Probabilistic sensitivity analysis for decision trees with multiple branches: Use of the Dirichlet distribution in a Bayesian framework","author":"AH Briggs","year":"2003","journal-title":"Medical Decision Making"},{"key":"pone.0261940.ref019","unstructured":"Zorginstituut Nederland. Drug prescription costs. [Internet. Accessed SEPTEMBER 27th, 2018. Website in Dutch] Available from: www.medicijnkosten.nl."},{"key":"pone.0261940.ref020","unstructured":"van der Ploeg, C.P.B., Pal, S., Vroome, E.D., Bossche, S. De kosten van ziekteverzuim voor werkgevers in nederland [Internet]. 2014. Available from: http:\/\/www.stresspreventionatwork.nl\/downloads\/brochure_kosten_ZV_NEA.pdf"},{"key":"pone.0261940.ref021","volume-title":"The Human and Economic Burden of Difficult-to-Treat Gouty Arthritis","author":"T Bardin","year":"2015"},{"key":"pone.0261940.ref022","article-title":"Making use of equity sensitive QALYs: A case study on identifying the worse off across diseases","author":"F Lindemark","year":"2014","journal-title":"Cost Eff Resour Alloc"},{"issue":"11","key":"pone.0261940.ref023","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/rheumatology\/ket265","article-title":"Health-related quality of life in gout: a systematic review","volume":"52","author":"P Chandratre","year":"2013","journal-title":"Rheumatology"},{"key":"pone.0261940.ref024","article-title":"Febuxostat for the management of hyperuricaemia in patients with gout: A nice single technology appraisal","author":"M Stevenson","year":"2011","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"pone.0261940.ref025","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3111\/13696998.2016.1149482","article-title":"Cost-effectiveness analysis of febuxostat in patients with gout in Spain","volume":"19","author":"F Perez-Ruiz","year":"2016","journal-title":"J Med Econ"},{"issue":"5","key":"pone.0261940.ref026","first-page":"453","article-title":"Cost-effectiveness of febuxostat in chronic gout","volume":"15","author":"SM Beard","year":"2014","journal-title":"Eur J Heal Econ"},{"key":"pone.0261940.ref027","article-title":"Cost-Effectiveness Analysis of Lesinurad\/Allopurinol Versus Febuxostat for the Management of Gout\/Hyperuricemia in Italy","author":"M Ruggeri","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"pone.0261940.ref028","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective","author":"CA Sarawate","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"pone.0261940.ref029","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/jama.2017.20189","article-title":"Lesinurad\/Allopurinol (Duzallo) for Gout-Associated HyperuricemiaLesinurad\/Allopurinol (Duzallo) for Gout-Associated HyperuricemiaLesinurad\/Allopurinol (Duzallo) for Gout-Associated Hyperuricemia","volume":"319","year":"2018","journal-title":"JAMA"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0261940","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T18:31:47Z","timestamp":1643394707000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0261940"}},"subtitle":[],"editor":[{"given":"Salah","family":"Ghabri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0261940","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]}}}